| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.032 | 0.5 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.5 |